The behavioral neurologist at NYU Langone Health and chief medical officer at Isaac Health shared his reaction to the recent approval of donanemab for patients with Alzheimer disease. [WATCH TIME: 7 minutes]
Joel Salinas, MD, MBA
Advertisement
Behavioral neurologist at NYU Langone and chief medical officer at Isaac Health.
Articles by Joel Salinas, MD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
How Multiple Sclerosis Affects Men
2
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
3
Trofinetide Leads to Real-World Improvements in Rett Syndrome Symptoms, LOTUS Study Finds
4
This Week on NeurologyLive® — October 13, 2025
5
